Navigation Links
Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
Date:8/19/2009

w' target='_new' target='_new' href='http://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=RODM'> RODM), acted as the exclusive placement agent for the offering.

A shelf registration statement relating to the shares of Series 2 Preferred Stock and warrants issued in the offering (and the shares of common stock issuable upon conversion of the Series 2 Preferred Stock and exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC"). The shelf registration statement was automatically effective upon filing with the SEC. A prospectus supplement relating to the offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting the Company at the following address: Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of Series 2 Preferred Stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading prices of the Company's securities. The risks and uncertainties include the risk that the investors might not exercise their warrants, the Company might not be able to continue to raise additional capital as needed to fund its operations, the Company's intentions regarding the use of proceeds, and other risk factors listed or described from time to time in the Company's filings with the SEC, including, without limitation, its most recent filings on Forms 10-K, 10-Q and 8-K. Except as required by law, the Company does not intend to update any of the statements in this press release upo
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
2. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
3. Cell Therapeutics, Inc. Announces Exercise of Overallotment
4. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
5. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
6. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
7. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
8. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
9. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
10. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
11. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 His Majesty ... Opening , The Court of His Majesty Willem-Alexander, King ... attend the Grand Opening of POET-DSM Advanced Biofuels’ Project ... Sept. 3. , The King will take part in ... activity, scheduled for 11 a.m.-12:20 p.m. and tour the ...
(Date:8/21/2014)... , Aug. 21, 2014 ... Immune Pharmaceuticals Inc., a biotechnology company, on its ... Immune previously traded on OTCQX®, the best marketplace ... OTC Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... on the successful execution of its growth strategy ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
(Date:8/20/2014)... often have it that American Indians largely were wiped ... influenza and tuberculosis brought to the New World by ... 20 million people lived in the Americas shortly before ... killed by European diseases., But new research led by ... Johannes Krause of the University of Tubingen in Germany ...
Breaking Biology Technology:His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3
... N.J., Jan. 21 Wedgewood Pharmacy has,announced ... (Bevacizumab) to,retinal specialists and ophthalmologists who request ... Avastin,s manufacturer, Genentech,s, decision,( http://www.lucentis.com/lucentis/pdf/announcement.pdf ) to ... of January 1., Avastin is commonly ...
... 21 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation ... of portions of the recently completed and ... planning for 2008,and employee recognition ceremonies., ... Mr. Zhang, Director and General Manager of ...
... chocolate present risk, OAKLAND, Calif., Jan. 21 ... whether from coffee, tea, caffeinated soda or hot,chocolate ... a new study,by the Kaiser Permanente Division of ... symptoms of nausea, vomiting and caffeine,aversion that tended ...
Cached Biology Technology:Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists 2Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists 3Kiwa Posts Video of 2007 Annual Management Meetings 2Kiwa Posts Video of 2007 Annual Management Meetings 3Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 3Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 4
(Date:8/21/2014)... in the journal Carcinogenesis by researchers at ... the protein adenomatous polyposis coli (APC) in suppressing colorectal ... the U.S. , Lead author Kristi Neufeld, associate professor ... the Cancer Biology program at the KU Cancer Center, ... to understand the various activities of APC, a protein ...
(Date:8/21/2014)... A team of researchers at Louisiana ... for using affordable, consumer-grade 3D printers and ... can contain antibacterial and chemotherapeutic compounds for ... of doctoral students and research faculty from ... programs collaborated to create filament extruders that ...
(Date:8/21/2014)... Carolina State University have developed a novel and versatile ... applications for creating new materials as well as for ... technique allows us to model much larger and more ... quickly," says Nan Li, lead author of a paper ... State,s Department of Materials Science and Engineering. "This is ...
Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... Atlantic right whale's future looks grim if the current ... professor of oceanography Douglas Nowacek and a group of ... co-authored a paper titled "North Atlantic Right Whales in ... the journal Science. , In it, Nowacek and his ...
... well-respected researcher who is now a chief of an immunology ... the boat in the past few years for the experts ... Matzinger has developed the "danger model," suggesting that the immune ... of a biological cell's death than with the introduction of ...
... new muscle complete with its own network of blood ... in a living mouse. The accomplishment is a first ... June 19 issue of Nature Biotechnology. , Lead researcher ... along with scientists from the Massachusetts Institute of Technology, ...
Cached Biology News:Scientists to mimic nature for newest cancer drugs 2Researchers seek to discover what really happens when a virus enters the body 2Researchers seek to discover what really happens when a virus enters the body 3New complete muscle grown in the lab 2
...
... Exiqon's miRCURY LNA technology enables sensitive and ... blotting. miRCURY LNA Detection probes have high ... and sensitive detection of miRNAs. Due to ... LNA probes less than 1/10 the amount ...
... E. coli Biotinylation Kit, Linear Template is designed ... expression kits. (Cat. No. 3 186 148, 3 ... generate linear expression constructs by PCR containing and ... combination of T7 RNA polymerase and prokaryotic cell ...
... (GR) Competitor Assay Kits are ideal for ... The PolarScreen GR Competitor Assay Kits contain ... and one of the following proprietary fluorescent ... GS Red (red assay kit), or GS ...
Biology Products: